Atracurium besylate is an intermediate-duration, non-depolarising, skeletal muscle relaxant for intravenous administration.
Use in adults:
The initial dosage for adults ranges from 0.3 to 0.6 mg/kg (depending on the duration of full block required) and will provide adequate relaxation for 15 to 35 minutes.
Use in children:
No dosage adjustments are required for paediatric patients two years of age or older. A dose of 0.4 mg/kg is recommended as the initial dose for paediatric patients aged 1 month to 2 years of age under halothane anaesthesia. Maintenance doses may be required with slightly greater frequency in infants and children than in adults.
Atracurium is a highly selective, competitive or non-depolarising neuromuscular blocking agent which is used as an adjunct to general anaesthesia to enable tracheal intubation to be performed and to relax skeletal muscles during surgery or controlled ventilation, and to facilitate mechanical ventilation in Intensive Care Unit (ICU) patients.
Kabitran Injection, 10 mg atracurium besylate in each mL.